# Tucidinostat Plus Apatinib for Advanced Osteosarcoma

> **NCT06125171** · PHASE2 · UNKNOWN · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 46 (estimated)

## Conditions studied

- Osteosarcoma

## Interventions

- **DRUG:** Tucidinostat, Apatinib

## Key facts

- **NCT ID:** NCT06125171
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-01
- **Primary completion:** 2024-12
- **Final completion:** 2025-12
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2023-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06125171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06125171, "Tucidinostat Plus Apatinib for Advanced Osteosarcoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06125171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*